Endocrine Abstracts

Introduction: There is currently high interest in the non-glycemic effects of incretin-based therapies, specifically glucagon-like peptide 1 (GLP-1) analogues, such as those on cardiovascular system. Liraglutide has been approved in Italy since one year to be prescribed in combination with oral hypoglycemic agents; it has several non-glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown...